What is Swixx BioPharma?
Swixx BioPharma operates as a dedicated agent for ethical pharmaceuticals, primarily serving research-based biopharmaceutical entities across Central and Eastern Europe (CEE). With its corporate headquarters situated in Baar, Switzerland, the company plays a crucial role in facilitating access to vital pharmaceutical agents for research and development within the region. The substantial enterprise-level funding indicates a strong market position and potential for significant expansion.
How much funding has Swixx BioPharma raised?
Swixx BioPharma has raised a total of $21.8M across 1 funding round:
Private Equity
$21.8M
Private Equity (2017): $21.8M with participation from HBM Healthcare
Key Investors in Swixx BioPharma
HBM Healthcare
HBM Healthcare Investments is a publicly traded investment company focused on the global healthcare sector, with a diversified portfolio of private and publicly listed companies. The firm aims to capitalize on the significant growth opportunities within the healthcare market, driven by demographic trends, medical advancements, and increasing demand for innovative therapies.
What's next for Swixx BioPharma?
The recent major strategic investment positions Swixx BioPharma for accelerated growth and enhanced operational capabilities. This capital infusion is expected to fuel further development of its agent network, expand its market reach within the CEE region, and potentially explore new therapeutic areas or service offerings. The company's trajectory suggests a focus on solidifying its role as a key partner for biopharma research and development.
See full Swixx BioPharma company page
